Validation of the European Organization for Research and Treatment of Cancer cervical cancer module for Chinese patients with cervical cancer

Cai-Hong Hua, Hui-Min Guo, Xin-Lei Guan, Fan-Jing Kong, Rui-Jie Hou, Xue-Ying Zhang, Shao-Ru Li Department of Gynecology and Obstetrics, First Affiliated Hospital of Xinxiang Medical University, Weihui City, Henan Province, People’s Republic of China Purpose: The aim of our study was to assess, for the first time, the validity, reliability, and acceptability of the European Organization for Research and Treatment of Cancer (EORTC) Quality Of Life questionnaire (QLQ) cervical cancer module (CX24) in Chinese cervical cancer patients. Patients and methods: One hundred fifteen outpatients with cervical cancer in the First Affiliated Hospital of Xinxiang Medical University from May 2013 to July 2013 were included in this study. All participants self-administered the EORTC QLQ-CX24 and the core questionnaire (EORTC QLQ-C30), and the Karnofsky Performance Scale was performed to evaluate scores. Data were analyzed with Cronbach’s a coefficient, Pearson correlation test, multitrait scaling analysis, and Mann–Whitney U test. Results: Scale reliability was confirmed by Cronbach’s a coefficients for internal consistency, which ranged from 0.71 to 0.82. Convergent and discriminant validity were confirmed by multitrait scaling analysis, which revealed three (3.4%) scaling errors for symptom experience scales and zero (0%) for body image as well as sexual/vaginal functioning scales. Higher missing value rate occurred in sexuality-related items. The clinical validity of the Chinese version of the EORTC QLQ-CX24 was demonstrated by the ability to discriminate among patients in different International Federation of Gynecology and Obstetrics stages. Conclusion: The EORTC QLQ-CX24 was proved to be a reliable and valid instrument with which to measure the quality of life in cervical cancer patients in the People’s Republic of China. Keywords: cervical cancer, quality of life, EORTC QLQ-CX24, People’s Republic of China Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Hua CH [verfasserIn] Guo HM [verfasserIn] Guan XL [verfasserIn] Kong FJ [verfasserIn] Hou RJ [verfasserIn] Zhang XY [verfasserIn] Li SR [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2013

Übergeordnetes Werk:	In: Patient Preference and Adherence - Dove Medical Press, 2008, (2013), default, Seite 1061-1066
Übergeordnetes Werk:	year:2013 ; number:default ; pages:1061-1066

Links:	Link aufrufen Link aufrufen Journal toc

Katalog-ID:	DOAJ077892259

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ077892259
003	DE-627
005	20230502130644.0
007	cr uuu---uuuuu
008	230228s2013 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)DOAJ077892259
035			\|a (DE-599)DOAJad1100bcda2647efb913e2736b23e44b
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a R5-920
100	0		\|a Hua CH \|e verfasserin \|4 aut
245	1	0	\|a Validation of the European Organization for Research and Treatment of Cancer cervical cancer module for Chinese patients with cervical cancer
264		1	\|c 2013
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Cai-Hong Hua, Hui-Min Guo, Xin-Lei Guan, Fan-Jing Kong, Rui-Jie Hou, Xue-Ying Zhang, Shao-Ru Li Department of Gynecology and Obstetrics, First Affiliated Hospital of Xinxiang Medical University, Weihui City, Henan Province, People’s Republic of China Purpose: The aim of our study was to assess, for the first time, the validity, reliability, and acceptability of the European Organization for Research and Treatment of Cancer (EORTC) Quality Of Life questionnaire (QLQ) cervical cancer module (CX24) in Chinese cervical cancer patients. Patients and methods: One hundred fifteen outpatients with cervical cancer in the First Affiliated Hospital of Xinxiang Medical University from May 2013 to July 2013 were included in this study. All participants self-administered the EORTC QLQ-CX24 and the core questionnaire (EORTC QLQ-C30), and the Karnofsky Performance Scale was performed to evaluate scores. Data were analyzed with Cronbach’s a coefficient, Pearson correlation test, multitrait scaling analysis, and Mann–Whitney U test. Results: Scale reliability was confirmed by Cronbach’s a coefficients for internal consistency, which ranged from 0.71 to 0.82. Convergent and discriminant validity were confirmed by multitrait scaling analysis, which revealed three (3.4%) scaling errors for symptom experience scales and zero (0%) for body image as well as sexual/vaginal functioning scales. Higher missing value rate occurred in sexuality-related items. The clinical validity of the Chinese version of the EORTC QLQ-CX24 was demonstrated by the ability to discriminate among patients in different International Federation of Gynecology and Obstetrics stages. Conclusion: The EORTC QLQ-CX24 was proved to be a reliable and valid instrument with which to measure the quality of life in cervical cancer patients in the People’s Republic of China. Keywords: cervical cancer, quality of life, EORTC QLQ-CX24, People’s Republic of China
653		0	\|a Medicine (General)
700	0		\|a Guo HM \|e verfasserin \|4 aut
700	0		\|a Guan XL \|e verfasserin \|4 aut
700	0		\|a Kong FJ \|e verfasserin \|4 aut
700	0		\|a Hou RJ \|e verfasserin \|4 aut
700	0		\|a Zhang XY \|e verfasserin \|4 aut
700	0		\|a Li SR \|e verfasserin \|4 aut
773	0	8	\|i In \|t Patient Preference and Adherence \|d Dove Medical Press, 2008 \|g (2013), default, Seite 1061-1066 \|w (DE-627)582018145 \|w (DE-600)2455848-5 \|x 1177889X \|7 nnns
773	1	8	\|g year:2013 \|g number:default \|g pages:1061-1066
856	4	0	\|u https://doaj.org/article/ad1100bcda2647efb913e2736b23e44b \|z kostenfrei
856	4	0	\|u http://www.dovepress.com/validation-of-the-european-organization-for-research-and-treatment-of--a14712 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1177-889X \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|j 2013 \|e default \|h 1061-1066

Indexfelder

author_variant	h c hc g h gh g x gx k f kf h r hr z x zx l s ls
matchkey_str	article:1177889X:2013----::aiainfherpaognztofreerhntetetfacrevclacroueoc
hierarchy_sort_str	2013
callnumber-subject-code	R
publishDate	2013
allfields	(DE-627)DOAJ077892259 (DE-599)DOAJad1100bcda2647efb913e2736b23e44b DE-627 ger DE-627 rakwb eng R5-920 Hua CH verfasserin aut Validation of the European Organization for Research and Treatment of Cancer cervical cancer module for Chinese patients with cervical cancer 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Cai-Hong Hua, Hui-Min Guo, Xin-Lei Guan, Fan-Jing Kong, Rui-Jie Hou, Xue-Ying Zhang, Shao-Ru Li Department of Gynecology and Obstetrics, First Affiliated Hospital of Xinxiang Medical University, Weihui City, Henan Province, People’s Republic of China Purpose: The aim of our study was to assess, for the first time, the validity, reliability, and acceptability of the European Organization for Research and Treatment of Cancer (EORTC) Quality Of Life questionnaire (QLQ) cervical cancer module (CX24) in Chinese cervical cancer patients. Patients and methods: One hundred fifteen outpatients with cervical cancer in the First Affiliated Hospital of Xinxiang Medical University from May 2013 to July 2013 were included in this study. All participants self-administered the EORTC QLQ-CX24 and the core questionnaire (EORTC QLQ-C30), and the Karnofsky Performance Scale was performed to evaluate scores. Data were analyzed with Cronbach’s a coefficient, Pearson correlation test, multitrait scaling analysis, and Mann–Whitney U test. Results: Scale reliability was confirmed by Cronbach’s a coefficients for internal consistency, which ranged from 0.71 to 0.82. Convergent and discriminant validity were confirmed by multitrait scaling analysis, which revealed three (3.4%) scaling errors for symptom experience scales and zero (0%) for body image as well as sexual/vaginal functioning scales. Higher missing value rate occurred in sexuality-related items. The clinical validity of the Chinese version of the EORTC QLQ-CX24 was demonstrated by the ability to discriminate among patients in different International Federation of Gynecology and Obstetrics stages. Conclusion: The EORTC QLQ-CX24 was proved to be a reliable and valid instrument with which to measure the quality of life in cervical cancer patients in the People’s Republic of China. Keywords: cervical cancer, quality of life, EORTC QLQ-CX24, People’s Republic of China Medicine (General) Guo HM verfasserin aut Guan XL verfasserin aut Kong FJ verfasserin aut Hou RJ verfasserin aut Zhang XY verfasserin aut Li SR verfasserin aut In Patient Preference and Adherence Dove Medical Press, 2008 (2013), default, Seite 1061-1066 (DE-627)582018145 (DE-600)2455848-5 1177889X nnns year:2013 number:default pages:1061-1066 https://doaj.org/article/ad1100bcda2647efb913e2736b23e44b kostenfrei http://www.dovepress.com/validation-of-the-european-organization-for-research-and-treatment-of--a14712 kostenfrei https://doaj.org/toc/1177-889X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2013 default 1061-1066
spelling	(DE-627)DOAJ077892259 (DE-599)DOAJad1100bcda2647efb913e2736b23e44b DE-627 ger DE-627 rakwb eng R5-920 Hua CH verfasserin aut Validation of the European Organization for Research and Treatment of Cancer cervical cancer module for Chinese patients with cervical cancer 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Cai-Hong Hua, Hui-Min Guo, Xin-Lei Guan, Fan-Jing Kong, Rui-Jie Hou, Xue-Ying Zhang, Shao-Ru Li Department of Gynecology and Obstetrics, First Affiliated Hospital of Xinxiang Medical University, Weihui City, Henan Province, People’s Republic of China Purpose: The aim of our study was to assess, for the first time, the validity, reliability, and acceptability of the European Organization for Research and Treatment of Cancer (EORTC) Quality Of Life questionnaire (QLQ) cervical cancer module (CX24) in Chinese cervical cancer patients. Patients and methods: One hundred fifteen outpatients with cervical cancer in the First Affiliated Hospital of Xinxiang Medical University from May 2013 to July 2013 were included in this study. All participants self-administered the EORTC QLQ-CX24 and the core questionnaire (EORTC QLQ-C30), and the Karnofsky Performance Scale was performed to evaluate scores. Data were analyzed with Cronbach’s a coefficient, Pearson correlation test, multitrait scaling analysis, and Mann–Whitney U test. Results: Scale reliability was confirmed by Cronbach’s a coefficients for internal consistency, which ranged from 0.71 to 0.82. Convergent and discriminant validity were confirmed by multitrait scaling analysis, which revealed three (3.4%) scaling errors for symptom experience scales and zero (0%) for body image as well as sexual/vaginal functioning scales. Higher missing value rate occurred in sexuality-related items. The clinical validity of the Chinese version of the EORTC QLQ-CX24 was demonstrated by the ability to discriminate among patients in different International Federation of Gynecology and Obstetrics stages. Conclusion: The EORTC QLQ-CX24 was proved to be a reliable and valid instrument with which to measure the quality of life in cervical cancer patients in the People’s Republic of China. Keywords: cervical cancer, quality of life, EORTC QLQ-CX24, People’s Republic of China Medicine (General) Guo HM verfasserin aut Guan XL verfasserin aut Kong FJ verfasserin aut Hou RJ verfasserin aut Zhang XY verfasserin aut Li SR verfasserin aut In Patient Preference and Adherence Dove Medical Press, 2008 (2013), default, Seite 1061-1066 (DE-627)582018145 (DE-600)2455848-5 1177889X nnns year:2013 number:default pages:1061-1066 https://doaj.org/article/ad1100bcda2647efb913e2736b23e44b kostenfrei http://www.dovepress.com/validation-of-the-european-organization-for-research-and-treatment-of--a14712 kostenfrei https://doaj.org/toc/1177-889X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2013 default 1061-1066
allfields_unstemmed	(DE-627)DOAJ077892259 (DE-599)DOAJad1100bcda2647efb913e2736b23e44b DE-627 ger DE-627 rakwb eng R5-920 Hua CH verfasserin aut Validation of the European Organization for Research and Treatment of Cancer cervical cancer module for Chinese patients with cervical cancer 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Cai-Hong Hua, Hui-Min Guo, Xin-Lei Guan, Fan-Jing Kong, Rui-Jie Hou, Xue-Ying Zhang, Shao-Ru Li Department of Gynecology and Obstetrics, First Affiliated Hospital of Xinxiang Medical University, Weihui City, Henan Province, People’s Republic of China Purpose: The aim of our study was to assess, for the first time, the validity, reliability, and acceptability of the European Organization for Research and Treatment of Cancer (EORTC) Quality Of Life questionnaire (QLQ) cervical cancer module (CX24) in Chinese cervical cancer patients. Patients and methods: One hundred fifteen outpatients with cervical cancer in the First Affiliated Hospital of Xinxiang Medical University from May 2013 to July 2013 were included in this study. All participants self-administered the EORTC QLQ-CX24 and the core questionnaire (EORTC QLQ-C30), and the Karnofsky Performance Scale was performed to evaluate scores. Data were analyzed with Cronbach’s a coefficient, Pearson correlation test, multitrait scaling analysis, and Mann–Whitney U test. Results: Scale reliability was confirmed by Cronbach’s a coefficients for internal consistency, which ranged from 0.71 to 0.82. Convergent and discriminant validity were confirmed by multitrait scaling analysis, which revealed three (3.4%) scaling errors for symptom experience scales and zero (0%) for body image as well as sexual/vaginal functioning scales. Higher missing value rate occurred in sexuality-related items. The clinical validity of the Chinese version of the EORTC QLQ-CX24 was demonstrated by the ability to discriminate among patients in different International Federation of Gynecology and Obstetrics stages. Conclusion: The EORTC QLQ-CX24 was proved to be a reliable and valid instrument with which to measure the quality of life in cervical cancer patients in the People’s Republic of China. Keywords: cervical cancer, quality of life, EORTC QLQ-CX24, People’s Republic of China Medicine (General) Guo HM verfasserin aut Guan XL verfasserin aut Kong FJ verfasserin aut Hou RJ verfasserin aut Zhang XY verfasserin aut Li SR verfasserin aut In Patient Preference and Adherence Dove Medical Press, 2008 (2013), default, Seite 1061-1066 (DE-627)582018145 (DE-600)2455848-5 1177889X nnns year:2013 number:default pages:1061-1066 https://doaj.org/article/ad1100bcda2647efb913e2736b23e44b kostenfrei http://www.dovepress.com/validation-of-the-european-organization-for-research-and-treatment-of--a14712 kostenfrei https://doaj.org/toc/1177-889X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2013 default 1061-1066
allfieldsGer	(DE-627)DOAJ077892259 (DE-599)DOAJad1100bcda2647efb913e2736b23e44b DE-627 ger DE-627 rakwb eng R5-920 Hua CH verfasserin aut Validation of the European Organization for Research and Treatment of Cancer cervical cancer module for Chinese patients with cervical cancer 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Cai-Hong Hua, Hui-Min Guo, Xin-Lei Guan, Fan-Jing Kong, Rui-Jie Hou, Xue-Ying Zhang, Shao-Ru Li Department of Gynecology and Obstetrics, First Affiliated Hospital of Xinxiang Medical University, Weihui City, Henan Province, People’s Republic of China Purpose: The aim of our study was to assess, for the first time, the validity, reliability, and acceptability of the European Organization for Research and Treatment of Cancer (EORTC) Quality Of Life questionnaire (QLQ) cervical cancer module (CX24) in Chinese cervical cancer patients. Patients and methods: One hundred fifteen outpatients with cervical cancer in the First Affiliated Hospital of Xinxiang Medical University from May 2013 to July 2013 were included in this study. All participants self-administered the EORTC QLQ-CX24 and the core questionnaire (EORTC QLQ-C30), and the Karnofsky Performance Scale was performed to evaluate scores. Data were analyzed with Cronbach’s a coefficient, Pearson correlation test, multitrait scaling analysis, and Mann–Whitney U test. Results: Scale reliability was confirmed by Cronbach’s a coefficients for internal consistency, which ranged from 0.71 to 0.82. Convergent and discriminant validity were confirmed by multitrait scaling analysis, which revealed three (3.4%) scaling errors for symptom experience scales and zero (0%) for body image as well as sexual/vaginal functioning scales. Higher missing value rate occurred in sexuality-related items. The clinical validity of the Chinese version of the EORTC QLQ-CX24 was demonstrated by the ability to discriminate among patients in different International Federation of Gynecology and Obstetrics stages. Conclusion: The EORTC QLQ-CX24 was proved to be a reliable and valid instrument with which to measure the quality of life in cervical cancer patients in the People’s Republic of China. Keywords: cervical cancer, quality of life, EORTC QLQ-CX24, People’s Republic of China Medicine (General) Guo HM verfasserin aut Guan XL verfasserin aut Kong FJ verfasserin aut Hou RJ verfasserin aut Zhang XY verfasserin aut Li SR verfasserin aut In Patient Preference and Adherence Dove Medical Press, 2008 (2013), default, Seite 1061-1066 (DE-627)582018145 (DE-600)2455848-5 1177889X nnns year:2013 number:default pages:1061-1066 https://doaj.org/article/ad1100bcda2647efb913e2736b23e44b kostenfrei http://www.dovepress.com/validation-of-the-european-organization-for-research-and-treatment-of--a14712 kostenfrei https://doaj.org/toc/1177-889X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2013 default 1061-1066
allfieldsSound	(DE-627)DOAJ077892259 (DE-599)DOAJad1100bcda2647efb913e2736b23e44b DE-627 ger DE-627 rakwb eng R5-920 Hua CH verfasserin aut Validation of the European Organization for Research and Treatment of Cancer cervical cancer module for Chinese patients with cervical cancer 2013 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Cai-Hong Hua, Hui-Min Guo, Xin-Lei Guan, Fan-Jing Kong, Rui-Jie Hou, Xue-Ying Zhang, Shao-Ru Li Department of Gynecology and Obstetrics, First Affiliated Hospital of Xinxiang Medical University, Weihui City, Henan Province, People’s Republic of China Purpose: The aim of our study was to assess, for the first time, the validity, reliability, and acceptability of the European Organization for Research and Treatment of Cancer (EORTC) Quality Of Life questionnaire (QLQ) cervical cancer module (CX24) in Chinese cervical cancer patients. Patients and methods: One hundred fifteen outpatients with cervical cancer in the First Affiliated Hospital of Xinxiang Medical University from May 2013 to July 2013 were included in this study. All participants self-administered the EORTC QLQ-CX24 and the core questionnaire (EORTC QLQ-C30), and the Karnofsky Performance Scale was performed to evaluate scores. Data were analyzed with Cronbach’s a coefficient, Pearson correlation test, multitrait scaling analysis, and Mann–Whitney U test. Results: Scale reliability was confirmed by Cronbach’s a coefficients for internal consistency, which ranged from 0.71 to 0.82. Convergent and discriminant validity were confirmed by multitrait scaling analysis, which revealed three (3.4%) scaling errors for symptom experience scales and zero (0%) for body image as well as sexual/vaginal functioning scales. Higher missing value rate occurred in sexuality-related items. The clinical validity of the Chinese version of the EORTC QLQ-CX24 was demonstrated by the ability to discriminate among patients in different International Federation of Gynecology and Obstetrics stages. Conclusion: The EORTC QLQ-CX24 was proved to be a reliable and valid instrument with which to measure the quality of life in cervical cancer patients in the People’s Republic of China. Keywords: cervical cancer, quality of life, EORTC QLQ-CX24, People’s Republic of China Medicine (General) Guo HM verfasserin aut Guan XL verfasserin aut Kong FJ verfasserin aut Hou RJ verfasserin aut Zhang XY verfasserin aut Li SR verfasserin aut In Patient Preference and Adherence Dove Medical Press, 2008 (2013), default, Seite 1061-1066 (DE-627)582018145 (DE-600)2455848-5 1177889X nnns year:2013 number:default pages:1061-1066 https://doaj.org/article/ad1100bcda2647efb913e2736b23e44b kostenfrei http://www.dovepress.com/validation-of-the-european-organization-for-research-and-treatment-of--a14712 kostenfrei https://doaj.org/toc/1177-889X Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 2013 default 1061-1066
language	English
source	In Patient Preference and Adherence (2013), default, Seite 1061-1066 year:2013 number:default pages:1061-1066
sourceStr	In Patient Preference and Adherence (2013), default, Seite 1061-1066 year:2013 number:default pages:1061-1066
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Medicine (General)
isfreeaccess_bool	true
container_title	Patient Preference and Adherence
authorswithroles_txt_mv	Hua CH @@aut@@ Guo HM @@aut@@ Guan XL @@aut@@ Kong FJ @@aut@@ Hou RJ @@aut@@ Zhang XY @@aut@@ Li SR @@aut@@
publishDateDaySort_date	2013-01-01T00:00:00Z
hierarchy_top_id	582018145
id	DOAJ077892259
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ077892259</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502130644.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2013 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ077892259</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJad1100bcda2647efb913e2736b23e44b</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R5-920</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Hua CH</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Validation of the European Organization for Research and Treatment of Cancer cervical cancer module for Chinese patients with cervical cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Cai-Hong Hua, Hui-Min Guo, Xin-Lei Guan, Fan-Jing Kong, Rui-Jie Hou, Xue-Ying Zhang, Shao-Ru Li Department of Gynecology and Obstetrics, First Affiliated Hospital of Xinxiang Medical University, Weihui City, Henan Province, People&rsquo;s Republic of China Purpose: The aim of our study was to assess, for the first time, the validity, reliability, and acceptability of the European Organization for Research and Treatment of Cancer (EORTC) Quality Of Life questionnaire (QLQ) cervical cancer module (CX24) in Chinese cervical cancer patients. Patients and methods: One hundred fifteen outpatients with cervical cancer in the First Affiliated Hospital of Xinxiang Medical University from May 2013 to July 2013 were included in this study. All participants self-administered the EORTC QLQ-CX24 and the core questionnaire (EORTC QLQ-C30), and the Karnofsky Performance Scale was performed to evaluate scores. Data were analyzed with Cronbach&rsquo;s a coefficient, Pearson correlation test, multitrait scaling analysis, and Mann&ndash;Whitney U test. Results: Scale reliability was confirmed by Cronbach&rsquo;s a coefficients for internal consistency, which ranged from 0.71 to 0.82. Convergent and discriminant validity were confirmed by multitrait scaling analysis, which revealed three (3.4%) scaling errors for symptom experience scales and zero (0%) for body image as well as sexual/vaginal functioning scales. Higher missing value rate occurred in sexuality-related items. The clinical validity of the Chinese version of the EORTC QLQ-CX24 was demonstrated by the ability to discriminate among patients in different International Federation of Gynecology and Obstetrics stages. Conclusion: The EORTC QLQ-CX24 was proved to be a reliable and valid instrument with which to measure the quality of life in cervical cancer patients in the People&rsquo;s Republic of China. Keywords: cervical cancer, quality of life, EORTC QLQ-CX24, People&rsquo;s Republic of China</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Guo HM</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Guan XL</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kong FJ</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hou RJ</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zhang XY</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Li SR</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Patient Preference and Adherence</subfield><subfield code="d">Dove Medical Press, 2008</subfield><subfield code="g">(2013), default, Seite 1061-1066</subfield><subfield code="w">(DE-627)582018145</subfield><subfield code="w">(DE-600)2455848-5</subfield><subfield code="x">1177889X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2013</subfield><subfield code="g">number:default</subfield><subfield code="g">pages:1061-1066</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/ad1100bcda2647efb913e2736b23e44b</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.dovepress.com/validation-of-the-european-organization-for-research-and-treatment-of--a14712</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1177-889X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2013</subfield><subfield code="e">default</subfield><subfield code="h">1061-1066</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Hua CH
spellingShingle	Hua CH misc R5-920 misc Medicine (General) Validation of the European Organization for Research and Treatment of Cancer cervical cancer module for Chinese patients with cervical cancer
authorStr	Hua CH
ppnlink_with_tag_str_mv	@@773@@(DE-627)582018145
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	R5-920
illustrated	Not Illustrated
issn	1177889X
topic_title	R5-920 Validation of the European Organization for Research and Treatment of Cancer cervical cancer module for Chinese patients with cervical cancer
topic	misc R5-920 misc Medicine (General)
topic_unstemmed	misc R5-920 misc Medicine (General)
topic_browse	misc R5-920 misc Medicine (General)
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Patient Preference and Adherence
hierarchy_parent_id	582018145
hierarchy_top_title	Patient Preference and Adherence
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)582018145 (DE-600)2455848-5
title	Validation of the European Organization for Research and Treatment of Cancer cervical cancer module for Chinese patients with cervical cancer
ctrlnum	(DE-627)DOAJ077892259 (DE-599)DOAJad1100bcda2647efb913e2736b23e44b
title_full	Validation of the European Organization for Research and Treatment of Cancer cervical cancer module for Chinese patients with cervical cancer
author_sort	Hua CH
journal	Patient Preference and Adherence
journalStr	Patient Preference and Adherence
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2013
contenttype_str_mv	txt
container_start_page	1061
author_browse	Hua CH Guo HM Guan XL Kong FJ Hou RJ Zhang XY Li SR
class	R5-920
format_se	Elektronische Aufsätze
author-letter	Hua CH
author2-role	verfasserin
title_sort	validation of the european organization for research and treatment of cancer cervical cancer module for chinese patients with cervical cancer
callnumber	R5-920
title_auth	Validation of the European Organization for Research and Treatment of Cancer cervical cancer module for Chinese patients with cervical cancer
abstract	Cai-Hong Hua, Hui-Min Guo, Xin-Lei Guan, Fan-Jing Kong, Rui-Jie Hou, Xue-Ying Zhang, Shao-Ru Li Department of Gynecology and Obstetrics, First Affiliated Hospital of Xinxiang Medical University, Weihui City, Henan Province, People’s Republic of China Purpose: The aim of our study was to assess, for the first time, the validity, reliability, and acceptability of the European Organization for Research and Treatment of Cancer (EORTC) Quality Of Life questionnaire (QLQ) cervical cancer module (CX24) in Chinese cervical cancer patients. Patients and methods: One hundred fifteen outpatients with cervical cancer in the First Affiliated Hospital of Xinxiang Medical University from May 2013 to July 2013 were included in this study. All participants self-administered the EORTC QLQ-CX24 and the core questionnaire (EORTC QLQ-C30), and the Karnofsky Performance Scale was performed to evaluate scores. Data were analyzed with Cronbach’s a coefficient, Pearson correlation test, multitrait scaling analysis, and Mann–Whitney U test. Results: Scale reliability was confirmed by Cronbach’s a coefficients for internal consistency, which ranged from 0.71 to 0.82. Convergent and discriminant validity were confirmed by multitrait scaling analysis, which revealed three (3.4%) scaling errors for symptom experience scales and zero (0%) for body image as well as sexual/vaginal functioning scales. Higher missing value rate occurred in sexuality-related items. The clinical validity of the Chinese version of the EORTC QLQ-CX24 was demonstrated by the ability to discriminate among patients in different International Federation of Gynecology and Obstetrics stages. Conclusion: The EORTC QLQ-CX24 was proved to be a reliable and valid instrument with which to measure the quality of life in cervical cancer patients in the People’s Republic of China. Keywords: cervical cancer, quality of life, EORTC QLQ-CX24, People’s Republic of China
abstractGer	Cai-Hong Hua, Hui-Min Guo, Xin-Lei Guan, Fan-Jing Kong, Rui-Jie Hou, Xue-Ying Zhang, Shao-Ru Li Department of Gynecology and Obstetrics, First Affiliated Hospital of Xinxiang Medical University, Weihui City, Henan Province, People’s Republic of China Purpose: The aim of our study was to assess, for the first time, the validity, reliability, and acceptability of the European Organization for Research and Treatment of Cancer (EORTC) Quality Of Life questionnaire (QLQ) cervical cancer module (CX24) in Chinese cervical cancer patients. Patients and methods: One hundred fifteen outpatients with cervical cancer in the First Affiliated Hospital of Xinxiang Medical University from May 2013 to July 2013 were included in this study. All participants self-administered the EORTC QLQ-CX24 and the core questionnaire (EORTC QLQ-C30), and the Karnofsky Performance Scale was performed to evaluate scores. Data were analyzed with Cronbach’s a coefficient, Pearson correlation test, multitrait scaling analysis, and Mann–Whitney U test. Results: Scale reliability was confirmed by Cronbach’s a coefficients for internal consistency, which ranged from 0.71 to 0.82. Convergent and discriminant validity were confirmed by multitrait scaling analysis, which revealed three (3.4%) scaling errors for symptom experience scales and zero (0%) for body image as well as sexual/vaginal functioning scales. Higher missing value rate occurred in sexuality-related items. The clinical validity of the Chinese version of the EORTC QLQ-CX24 was demonstrated by the ability to discriminate among patients in different International Federation of Gynecology and Obstetrics stages. Conclusion: The EORTC QLQ-CX24 was proved to be a reliable and valid instrument with which to measure the quality of life in cervical cancer patients in the People’s Republic of China. Keywords: cervical cancer, quality of life, EORTC QLQ-CX24, People’s Republic of China
abstract_unstemmed	Cai-Hong Hua, Hui-Min Guo, Xin-Lei Guan, Fan-Jing Kong, Rui-Jie Hou, Xue-Ying Zhang, Shao-Ru Li Department of Gynecology and Obstetrics, First Affiliated Hospital of Xinxiang Medical University, Weihui City, Henan Province, People’s Republic of China Purpose: The aim of our study was to assess, for the first time, the validity, reliability, and acceptability of the European Organization for Research and Treatment of Cancer (EORTC) Quality Of Life questionnaire (QLQ) cervical cancer module (CX24) in Chinese cervical cancer patients. Patients and methods: One hundred fifteen outpatients with cervical cancer in the First Affiliated Hospital of Xinxiang Medical University from May 2013 to July 2013 were included in this study. All participants self-administered the EORTC QLQ-CX24 and the core questionnaire (EORTC QLQ-C30), and the Karnofsky Performance Scale was performed to evaluate scores. Data were analyzed with Cronbach’s a coefficient, Pearson correlation test, multitrait scaling analysis, and Mann–Whitney U test. Results: Scale reliability was confirmed by Cronbach’s a coefficients for internal consistency, which ranged from 0.71 to 0.82. Convergent and discriminant validity were confirmed by multitrait scaling analysis, which revealed three (3.4%) scaling errors for symptom experience scales and zero (0%) for body image as well as sexual/vaginal functioning scales. Higher missing value rate occurred in sexuality-related items. The clinical validity of the Chinese version of the EORTC QLQ-CX24 was demonstrated by the ability to discriminate among patients in different International Federation of Gynecology and Obstetrics stages. Conclusion: The EORTC QLQ-CX24 was proved to be a reliable and valid instrument with which to measure the quality of life in cervical cancer patients in the People’s Republic of China. Keywords: cervical cancer, quality of life, EORTC QLQ-CX24, People’s Republic of China
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	default
title_short	Validation of the European Organization for Research and Treatment of Cancer cervical cancer module for Chinese patients with cervical cancer
url	https://doaj.org/article/ad1100bcda2647efb913e2736b23e44b http://www.dovepress.com/validation-of-the-european-organization-for-research-and-treatment-of--a14712 https://doaj.org/toc/1177-889X
remote_bool	true
author2	Guo HM Guan XL Kong FJ Hou RJ Zhang XY Li SR
author2Str	Guo HM Guan XL Kong FJ Hou RJ Zhang XY Li SR
ppnlink	582018145
callnumber-subject	R - General Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
callnumber-a	R5-920
up_date	2024-07-03T14:45:28.289Z
_version_	1803569519178809344
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ077892259</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502130644.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2013 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ077892259</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJad1100bcda2647efb913e2736b23e44b</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R5-920</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Hua CH</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Validation of the European Organization for Research and Treatment of Cancer cervical cancer module for Chinese patients with cervical cancer</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Cai-Hong Hua, Hui-Min Guo, Xin-Lei Guan, Fan-Jing Kong, Rui-Jie Hou, Xue-Ying Zhang, Shao-Ru Li Department of Gynecology and Obstetrics, First Affiliated Hospital of Xinxiang Medical University, Weihui City, Henan Province, People&rsquo;s Republic of China Purpose: The aim of our study was to assess, for the first time, the validity, reliability, and acceptability of the European Organization for Research and Treatment of Cancer (EORTC) Quality Of Life questionnaire (QLQ) cervical cancer module (CX24) in Chinese cervical cancer patients. Patients and methods: One hundred fifteen outpatients with cervical cancer in the First Affiliated Hospital of Xinxiang Medical University from May 2013 to July 2013 were included in this study. All participants self-administered the EORTC QLQ-CX24 and the core questionnaire (EORTC QLQ-C30), and the Karnofsky Performance Scale was performed to evaluate scores. Data were analyzed with Cronbach&rsquo;s a coefficient, Pearson correlation test, multitrait scaling analysis, and Mann&ndash;Whitney U test. Results: Scale reliability was confirmed by Cronbach&rsquo;s a coefficients for internal consistency, which ranged from 0.71 to 0.82. Convergent and discriminant validity were confirmed by multitrait scaling analysis, which revealed three (3.4%) scaling errors for symptom experience scales and zero (0%) for body image as well as sexual/vaginal functioning scales. Higher missing value rate occurred in sexuality-related items. The clinical validity of the Chinese version of the EORTC QLQ-CX24 was demonstrated by the ability to discriminate among patients in different International Federation of Gynecology and Obstetrics stages. Conclusion: The EORTC QLQ-CX24 was proved to be a reliable and valid instrument with which to measure the quality of life in cervical cancer patients in the People&rsquo;s Republic of China. Keywords: cervical cancer, quality of life, EORTC QLQ-CX24, People&rsquo;s Republic of China</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Guo HM</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Guan XL</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Kong FJ</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Hou RJ</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Zhang XY</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Li SR</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Patient Preference and Adherence</subfield><subfield code="d">Dove Medical Press, 2008</subfield><subfield code="g">(2013), default, Seite 1061-1066</subfield><subfield code="w">(DE-627)582018145</subfield><subfield code="w">(DE-600)2455848-5</subfield><subfield code="x">1177889X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">year:2013</subfield><subfield code="g">number:default</subfield><subfield code="g">pages:1061-1066</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/ad1100bcda2647efb913e2736b23e44b</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.dovepress.com/validation-of-the-european-organization-for-research-and-treatment-of--a14712</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1177-889X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="j">2013</subfield><subfield code="e">default</subfield><subfield code="h">1061-1066</subfield></datafield></record></collection>
score	7.4023323

Nicht das Richtige dabei?

Schreiben Sie uns!

Validation of the European Organization for Research and Treatment of Cancer cervical cancer module for Chinese patients with cervical cancer

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?